Personalized Computer Simulation of Diastolic Function in Heart Failure

Ali Amr, Elham Kayvanpour, Farbod Sedaghat-Hamedani, Tiziano Passerini, Viorel Mihalef, Alan Lai, Dominik Neumann, Bogdan Georgescu, Sebastian Buss, Derliz Mereles, Edgar Zitron, Andreas E. Posch, Maximilian Würtste, Tommaso Mansi, Hugo A. Katus, Benjamin Meder

1 Institute for Cardiomyopathies, Department of Medicine III, University of Heidelberg, 69120 Heidelberg, Germany
2 German Centre for Cardiovascular Research (DZHK), Heidelberg/Mannheim, Germany
3 Siemens Healthcare, Medical Imaging Technologies, Princeton, NJ 08540, USA
4 Siemens Healthcare, Strategy and Innovation, 91052 Erlangen, Germany

Received 29 February 2016; revised 21 April 2016; accepted 26 April 2016
Available online 29 July 2016

Handled by Andreas Keller

Abstract

The search for a parameter representing left ventricular relaxation from non-invasive and invasive diagnostic tools has been extensive, since heart failure (HF) with preserved ejection fraction (HF-pEF) is a global health problem. We explore here the feasibility using patient-specific cardiac computer modeling to capture diastolic parameters in patients suffering from different degrees of systolic HF. Fifty eight patients with idiopathic dilated cardiomyopathy have undergone thorough clinical evaluation, including cardiac magnetic resonance imaging (MRI), heart catheterization, echocardiography, and cardiac biomarker assessment. A previously-introduced framework for personalized computer simulation of diastolic function in heart failure is applied to clinical data from these patients. The results provide evidence that personalized computer simulation can capture diastolic parameters in patients with different degrees of systolic HF.
Introduction

The application of computational modeling to different organ systems has been gathering increasing interest from the research community. The possibility of performing *in silico* experiments on computer models that mimic patient's organs has revved up the momentum of the evolution of virtual patient-specific models. The surge of interest has been driven by the prospect of being able to control all the variables to open up new possibilities toward better health care in a risk-free and ethically acceptable setting for the patient. The exponential growth of computational imaging capacities has also broadened the possibilities toward such models. From simplistic models based on geometric shapes as early as the 1960s to multi-scale multi-physics models, the transformation in this field has been tremendous [1–6].

Heart failure (HF) remains the leading cause of death in developed countries [7–9]. The increasingly high incidence rates, hospitalization, and health expenditures compel a constant call for new strategies and progress in this field [10]. HF is a syndrome with diverse etiologies, characterized by the decline of cardiac systolic or diastolic function, resulting in insufficient blood supply to organs, organ dysfunction, and finally, failure [11–13].

A chronological retrospective analysis of HF therapy in patients with dilated cardiomyopathy (DCM) in the last century sheds light on difficulties in treating this disease. Expert guidelines currently outline HF therapy based on patients' clinical presentation, cardiac systolic function, and specific biomarkers, but overuse, to some extent, the pathophysiology and etiology that lead to reduced cardiac function [13]. These rigid therapy regimes focus on relieving cardiac symptoms and tackle less the individual progression and the cause leading to this disease. Over the past three decades, drug therapy has undergone rapid progression in lowering the mortality and morbidity rates in HF patients [14]. The mortality rates of patients that present with progressed HF symptoms and receive optimal medical therapy remain high [14,15]. Even the latest drug advancements present only a stepping stone toward the treatment of HF. The diversity of this disease, in its etiology and clinical presentation, suggests that the key to a better and cost-effective therapy is the individualized and personalized care. Personalized cardiac models have the potential in facilitating the achievement of this goal [16,17].

The role of left ventricular (LV) systolic dysfunction has attracted broad attention from both clinical and experimental researchers [18–23]. On the other hand, LV diastolic dysfunction has been relatively slow in gathering interest due to its complex role in the pathomechanism of HF [24,25]. General consensus defines LV diastolic dysfunction as irregular cardiac functional relaxation, distensibility, and LV filling, which causes higher end diastolic left ventricular pressures [26]. To completely understand the pathogenesis of diastolic dysfunction, a broad appreciation of cardiac physiology in the diastole and its diverse compensation mechanisms is needed. Dyspnea, as a symptom of HF, is often attributed to diastolic dysfunction after exclusion of other probable causes [27–30]. Its diagnosis remains a challenge in clinical settings because of the difficulties present in linearly quantifying the progression of this disease and assessing its significance to the patient [31]. The current non-invasive gold standard for the assessment of diastolic dysfunction remains the echocardiographic evaluation, especially Doppler measurements of transmitral flow and tissue Doppler imaging (TDI) [26].

The progress in the field of cardiac simulation has been on a rise in the last decade [32]. One of the first challenges in cardiac modeling is capturing the anatomical geometry of the heart. Simulating cardiac physical parameters relies heavily on ventricular geometry. Many of the early-proposed cardiac anatomical estimations were either based on geometrical models or post-mortem heart dissections. The first simplifications of the complex LV geometry have been based on spherical models [33]. Koushanpour and colleagues published one of the early simulations of LV dynamics based on spheroids in 1960s [34]. In this study, they compared the LV time course of tension using Laplace's surface tension law in cats and turtles. Their findings highlighted the importance of cardiac size and shape in determining LV function. A gradual shift toward anatomical models, based on *ex vivo* human and animal hearts, could be observed, capturing a more accurate representation of cardiac anatomy [35–37].

Progress in other fields of science, especially in physics and mathematics, and advancements in computer technology opened up new possibilities toward improving existing computer simulations. The application of the finite element method in diverse sectors of engineering represented one of the major turning points in cardiac computational modeling and simulation. The conception and refinement of this method enabled the analysis of complex structural and mathematical problems [38,39]. Janz et al. introduced one of the early cardiac mechanical models using the finite element method [40]. The cardiac model, in which the anatomical geometry is estimated from the hearts of Sprague–Dawley albino male rats, seemed to predict the gross free wall deformation with the assumption of an elastically linear and heterogeneous tissue [40]. Vinson et al. later described a human cardiac model using “36 brick type finite elements” representing the left ventricle [40]. As pointed out by the authors, one of the limiting factors at that time was creating multi-scale patient-specific cardiac models has been applied on all these patients. Novel parameters, such as global stiffness factor and maximum left ventricular active stress, representing cardiac active and passive tissue properties have been computed for all patients. Invasive pressure measurements from heart catheterization were then used to evaluate ventricular relaxation using the time constant of isovolumic relaxation Tau (τ). Parameters from heart catheterization and the multi-scale model have been evaluated and compared to patient clinical presentation. The model parameter global stiffness factor, representing diastolic passive tissue properties, is correlated significantly across the patient population with τ. This study shows that multi-modal cardiac models can successfully capture diastolic (dys) function, a prerequisite for future clinical trials on HF-pEF.
“the capacity of the computer and computing time available” [41]. Today, current smart phones have more processing power than the computers used at that time.

The radical advances in cardiac imaging modalities and the implementation of non-invasive imaging sequences into the diagnostic algorithms marked the shift toward image-based models and allowed faster transition toward patient-specific cardiac models [42]. Most computational models to date selectively integrate elements (such as myocardial structure, structural pathologies, biomechanics, or electrophysiology) in various details and complexity, to suit the objective of the model [43].

We have proposed previously a patient-specific cardiac model that captures the biomechanical, hemodynamic, and electrophysiological cardiac functions in patients with DCM [2]. In this paper, we explore the feasibility of using such models to capture cardiac diastolic function in a similar patient population.

Results and discussion

Clinical characteristics of the patient population

A summary of the clinical parameters investigated in this study is presented in Table 1. The patients in our cohort are 54 years old on average. The majority of the recruited patients showed signs of HF with assessment of the New York Heart Association (NYHA) functional class II and III. The left ventricular ejection fraction (LV-EF) was 37%, with 5% of the recruited patients having an ejection fraction above 55%. HF drug therapy was initiated for all patients. The descriptive analysis of the invasive pressure measurements is presented in Table 2. As can be seen, the mean left ventricular end diastolic pressure (LV-EDP; mean 22 mmHg), the pulmonary capillary wedge pressure (PCWP; mean 20 mmHg), and the systolic pulmonary artery pressure (SAP; mean 40 mmHg) were all elevated as expected from the largely-symptomatic patient cohort. The calculated time constant Tau (τ) across the study population ranged 28–89 ms as shown in Figure 1A. Taking together the elevated pressure measured from the right circulation, approximately 40% of the patients proved to have a lengthened τ (duration >48 ms [44]), a sign of abnormal left ventricular relaxation.

Simulation of cardiac parameters

The feasibility of using the presented cardiac model to capture cardiac systolic function in a clinical setting, in its strengths and limitations, has been previously reported [2]. In the present study, we aimed to examine how systolic and diastolic biomechanical parameters derived from the model, after completion of the fitting and personalization process, correspond to invasive and non-invasive clinical parameters of diastolic function. An example of a generated cardiac model of a patient in this study, after concluding the workflow algorithm, is shown in Figure 2. The systolic parameters, including computed LV-EF (cLV-EF; mean 35%), simulated stroke volume (sSV; mean 86 ml), maximum strength of active contraction (s0; mean 120 kPa), and global stiffness factor (HO factor; mean 1.1), are computed from the cardiac models for each patient as shown in Table 3. The distribution of global stiffness

| Patient characteristics | Value         |
|-------------------------|---------------|
| Age, mean ± SD, year    | 53.7 ± 12.6   |
| Age at onset ± SD, year | 52.8 ± 12.8   |
| BMI, mean ± SD, kg/m²  | 27 ± 5.6      |
| Heart rate, mean ± SD, beats/min | 78 ± 20 |
| Blood pressure, mean ± SD, mmHg | 122 ± 17 |
| Systolic, mmHg          | 77 ± 11       |
| Diastolic, mmHg         | 9 ± 19        |
| Diabetes, number (%)    | 13 (22%)      |
| Atrial fibrillation, number (%) | 9 (16%) |
| 6MWT, mean ± SD, m      | 511 ± 120     |
| Dyspnoea, number (%)    | 11 (19%)      |
| NYHA I                  | 11 (19%)      |
| NYHA II                 | 28 (48%)      |
| NYHA III                | 17 (30%)      |
| NYHA IV                 | 2 (3%)        |
| Family history of SCD or DCM, number (%) | 11 (19%) |

Laboratory tests

- White blood cell count, mean ± SD, /nl 7.8 ± 2.4
- Hemoglobin, mean ± SD, g/dl 14.1 ± 1.5
- eGFR, mean ± SD, ml/min/1.73 m² 88.6 ± 16.3
- Creatinine, mean ± SD, mg/dl 0.9 ± 0.2
- NT-proBNP, median (1Q;3Q), ng/l 767 (104;2385)
- hs-TNT, median (1Q;3Q), pg/ml 16(8;38)
- Medications, number (%)
  - Aspirin 20 (36%)
  - ß-blocker 54 (93%)
  - ACE inhibitor or ARB 58 (100%)
  - Loop diuretic 30 (54%)
  - Aldosterone antagonist 35 (60%)
  - Statin 24 (44%)
  - Digoxin 7 (12%)

Echocardiography

- LV ejection fraction, mean ± SD, % 32 ± 15
- LV-EDD, mean ± SD, mm/m² 57 ± 9
- LV-ESD, mean ± SD, mm/m² 43 ± 13

MRI

- LV ejection fraction, mean ± SD,% 37 ± 15
- LV stroke volume, mean ± SD, ml 84 ± 28
- LV-ESV index, mean ± SD, ml/m² 85 ± 57
- LV-EDV index, mean ± SD, ml/m² 130 ± 54
- LV-ESD index, mean ± SD, mm²/m² 26 ± 7
- LV-EDD index, mean ± SD, mm²/m² 31 ± 5
- LV mass index, mean ± SD, g/m² 59 ± 21

Note: 6MWT, 6 Minute Walk Test; NYHA, New York Heart Association functional classification; SCD, sudden cardiac death; DCM, dilated cardiomyopathy; eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; hs-TNT, high sensitive troponin T; ACE, angiotensin-converting-enzyme; ARB, angiotensin II receptor blocker; LV, left ventricular; EDD, end diastolic diameter; ESD, end systolic diameter; MRI, magnetic resonance imaging; ESV, end systolic volume; EDV, end diastolic volume.

Table 2: Clinical characteristics of the recruited patients

Table 3: Distribution of global stiffness
echocardiographic TDI parameters in humans [46], the search for a parameter representing left ventricular relaxation from non-invasive and invasive diagnostic tools has been extensive [44]. The diastolic function of the heart is largely dependent on the passive myocardial properties, such as myocardial stiffness, which represents the effective elasticity of cardiac extra and intracellular composition. Preload, myocardial contractility, and regional dyssynchrony modulate myocardial relaxation [25]. The accurate characterization and assessment of diastolic dysfunction requires the simultaneous measurement of pressure and volume changes in the left ventricle during the diastole, which increases the complexity and difficulty of its precise clinical evaluation in living patients. Tau (τ), the time constant of isovolumic relaxation, is acknowledged as the time period needed for the ventricular pressure to fall to approximately 37% (or 1/e) of the pressure at the start of the isovolumic relaxation phase [47]. We used τ in this study, as a measure for the cardiac diastolic function, because τ remains a widely-accepted, less load-dependent surrogate for left ventricular relaxation and pressure decline [47,48].

To assess the ability of the personalized cardiac model in capturing left ventricular relaxation, we correlated the model parameter of left ventricular global stiffness with τ. As presented in Table 4 and Figure 3A, there is a significant correlation (P = 4.1E−4) between the global stiffness factor and τ, whereas no significant correlation was found between left ventricular maximum active stress and τ. N-terminal pro-brain natriuretic peptide (NT-proBNP) is accepted as a prognostic biomarker in both systolic and diastolic HF [13,49,50]. We extended the analysis by subdividing the study population into patients with normal and elevated NT-proBNP plasma concentration (cut-off value of 125 ng/l). Interestingly, the correlation between global stiffness factor and τ was not only preserved but enhanced in the subpopulation with elevated NT-proBNP (125 ng/l) as shown in Table 4 and Figure 3B. The correlation between these two parameters was also preserved (R = 0.58, P < 0.05), with a higher cut-off level of 325 ng/l for NT-proBNP. At the same time, the correlation between LV maximum active stress, which represents the active and systolic component of myocardial contraction in the model, and τ remained non-significant. This observation underlines the potential benefit of combining molecular biomarkers with computational models.

Doppler echocardiography remains the current reference method for non-invasive assessment of diastolic LV function. Kasner et al. performed a clinical study evaluating the correlation between conventional or TDI echocardiographic diastolic indexes and pressure volume measurements from heart catheterization. E’ (early diastolic peak of the annular TDI measurements), E/E’ (ratio of transmitral flow and annular velocity), E/A’ (ratio of early and late annular velocity) showed very modest correlations with τ of −0.33, 0.34, and −0.24, respectively [51]. Although the presented correlation between global stiffness factor and τ appears modest, it remains at least on the same level as those between τ and the echocardiographic parameters mentioned above.

Table 2 Summary of invasive pressure measurements and calculations

| Parameter                                | Value                         |
|------------------------------------------|-------------------------------|
| Left ventricular end-diastolic pressure, mean ± SD, mmHg | 22 ± 8.8                     |
| Pulmonary capillary wedge pressure, mean ± SD, mmHg       | 20 ± 9.1                     |
| Mean pulmonary artery pressure, mean ± SD, mmHg           | 28 ± 11.2                    |
| Systolic pulmonary artery pressure, mean ± SD, mmHg       | 40 ± 13.4                    |
| \( (-dP/dt)_{\text{max}} \), mean ± SD, mmHg/s            | 1381 ± 404                   |
| \( (+dP/dt)_{\text{max}} \), mean ± SD, mmHg/s             | 1306 ± 488                   |
| Tau (τ), mean ± SD, ms                      | 49 ± 13.3                    |

Figure 1 Distribution of the examined variables

Distribution of the calculated time constant Tau (τ; A), global stiffness factor (B), and LV maximum active stress (C) across the study population is plotted. The brown bars represent the frequency density and the red lines represent the distribution curve overlay for each variable. LV, left ventricle.
The clinical applicability of using in silico 3D computational cardiac models is promising, which strengthens the predilection toward its utilization in search of novel perspectives in risk stratification, therapy, and prognosis in other fields of cardiology [17]. The incentive toward the search for a better strategy to diagnose and evaluate diastolic dysfunction stems from the heterogeneity of results in clinical studies investigating HF with preserved EF (HF-PEF), with respect to mortality, quality of life, and cardiovascular risk [52]. The commonly-accepted consensus, which has prevailed over the years, remains that HF-PEF is associated with increased mortality and hospitalization [52–54]. As a diagnosis of exclusion for patients presenting with dyspnea and other HF symptoms, HF-PEF presents a challenge to physicians especially in an ambulatory setting. The differences in patient characteristics and demographics between patients with HF-PEF and those carrying HF with reduced EF (HF-REF) have raised further questions about the disease pathomechanism, severity, and clinical significance. In this study, we show that this personalized cardiac model can capture patient-specific diastolic parameters, which could hold the key toward solving difficult challenges in patients with HF-PEF.

More and more accurate and detailed models of cardiac function in both humans and animals have been abundantly reported, including biomechanical models that specifically investigate cardiac diastolic function [55–59]. However, few
models integrate data from conventional standard clinical procedures to create a patient-specific electro-mechanical heart model. This study presents the feasibility of applying and integrating various experimentally-validated biophysical models to create a patient-specific multi-modal simulation of cardiac function in the diseased heart.

Our goal is the constant progression of the implementation of virtual cardiac models in a clinical setting to provide the patients with the optimal individualized medical care. Further advancement of computational modeling at different levels is anticipated in the near future. One of the first steps forward is validating the predictive prognostic power of such virtual models in a clinical setting. Secondly, capturing patient-specific cardiac fiber architecture remains one of the challenges and a limiting factor of advanced in vivo virtual models nowadays. The importance of fiber orientation in simulating cardiac electrophysiology and biomechanics has been abundantly described in previous studies [60] and diffusion tension MRI (DT-MRI) serves as a common approach to capture cardiac fiber orientation [61]. Due to technical difficulties present, like scan duration, myocardial respiratory displacement, and short transversal relaxation time, high resolution DT-MRI imaging was mainly utilized on explanted animal and human hearts. Algorithms for rule-based assignment of fiber orientation currently provide alternative to in vivo virtual models [62]. However, recent advances in cardiac DT-MRI render this approach feasible in the near future [63], opening up the possibility toward generating fully patient-specific myocardial fiber orientation and architecture. On another level, integrating not only parameters of cardiac electrophysiology but also histopathological myocardial structure and tissue specific passive physical parameters, like tensile strength, compaction and density of fibers, and fibrosis grade, from myocardial biopsies could be promising toward the complete in silico simulation of the individual heart.

**Materials and methods**

**Patient population**

Patients with HF symptoms were enrolled in this study after having given their written informed consent. Only patients receiving heart catheterization due to clinical necessity were included. To reflect broad representation of potential HF phenotypes, cases with slightly to severely reduced systolic function were included. Clinical evaluation, diagnostics, and follow-up were performed in adherence to hospital guidelines. The enrolled patients underwent comprehensive clinical assessment constituting a detailed clinical history, physical examination, 12 lead electrocardiogram, echocardiography, 6 Minute Walk Test, spiroergometry, and comprehensive laboratory tests including NT-proBNP. For the clinical diagnostic process, patients underwent also procedures to ensure exclusion of secondary causes of DCM (left heart catheterization, cardiac MRI, extensive blood panel, and clinical history). Acute myocarditis, significant coronary artery disease (CAD), history of chemotherapy with cardio-toxic agents or chest radiation, valvular heart diseases, and probable secondary causes for DCM were exclusion criteria. A total number of \( n = 58 \) patients were investigated in this study.

**Hemodynamic data acquisition**

Hemodynamic assessment was performed using left and right heart catheterization. All pressure curves were checked for calibration errors. The customary femoral access was used in all patients receiving simultaneous left and right circulation evaluation. Pressure measurements of the left ventricle and aorta were performed over repeated cardiac cycles prior to application of the contrast agent. Hemodynamic pressure analysis
was performed using the computer-assisted software Metek (Roetgen, Germany). The intraventricular rate of change in pressure \((-\frac{dP}{dt})\) was calculated during the procedure. Maximum values for \((-\frac{dP}{dt})\) were identified and output for each cardiac cycle. The calculation of \(\tau\) (time constant of isovolumic relaxation) was based on the approach described by Weiss and colleagues [64], which assumes an exponential decline in left ventricular pressure during the isovolumic time period. \(P(t) = P(t = 0) e^{-t/\tau}\) and \(\tau = -P/(dP/dt)\).

**MR data acquisition**

To further evaluate the clinical phenotype, all patients underwent cardiac MRI analyses (1.5T cMRI, 32Ch RF platform, Philips Achieva). Standard multi-slice 2D steady-state free precession sequences (SSFP), late gadolinium enhancement (LGE) multi-slice inversion recovery sequence, and feature tracking imaging were included in the procedure protocols. Comprehensive 2D echocardiographic assessment of systolic and diastolic function according to current guidelines and hospital standards was also performed in all patients.

**Personalized cardiac model in patients with dilated cardiomyopathy**

The computational workflow and process of simulating the personalized multi-scale multi-physics model based on the acquired clinical data has been thoroughly described previously [2]. We briefly recall here the model assumptions related more specifically to the description of cardiac biomechanics. We adopt the Hill–Maxwell framework to represent the interplay between active contraction and passive response of the myocardium [65] (Figure 4).

The myocyte contraction is modeled following the approach presented by Serresant and colleagues, for which the contraction is related to the action potential through a bi-exponential law [66]. We parameterize this law by the maximum strength of active contraction (s0), the rate of contraction (the speed at which the tissue contracts during depolarization), and the rate of relaxation (the speed at which the tissue relaxes during repolarization). The passive response of the myocardium to mechanical stress is described by the non-linear, hyper-elastic and orthotropic tissue model proposed by Holzapfel and colleagues [67]. We consider a global scaling factor (HO factor) for the reference model parameters provided by Holzapfel and colleagues, offering a lumped representation of the tissue stiffness [67]. The electromechanical model provides computed cardiac dynamics, from which we extract simulated ejection fraction as the clinical parameter of interest. More details on the personalized cardiac model can be found in the references cited in this section.

**Statistical analysis**

The statistical analysis was performed using the conventional “R” software (Version 3.2.2). The parameters \(\tau\), global stiffness factor, and LV active force are continuous and show an approximate normal distribution. Therefore, a linear correlation analysis using Pearson’s correlation coefficient through the “cor” and the “cor.test” function was applied. The parameters \(P\) value, with a significance level of 0.05, was computed for all performed correlations. To account for a possible non-linear relationship between \(\tau\) and global stiffness factor, a logarithmic analysis of both parameters is also presented (Table S1). A possible monotonic correlation was analyzed using the Spearman rank correlation method. The results obtained were similar but non-superior to those based on the linear correlation analysis and were not presented in the current study to avoid repetition. Histograms were calculated using the “hist” function with standard parameters. In order to visualize the output, scatter plots were generated for the significant correlations. Smoothing of scatter plots was carried out by the “smoothScatter” function.

**Authors’ contributions**

BM, AA, EK, FS, and TM designed the study; AA, FS, HK, EK, BM, DM, EZ, and SB carried out patient data acquisition; TM, TP, VM, DN, BG, AEP and MW performed the computational analysis, and AL, AA, BM, FS, and EK carried out statistical analysis. AA, EK, BM, TM, TP, DM, and HK were involved in manuscript drafting and revision. All authors read and approved the final manuscript.

**Competing interests**

This work was in part conducted within an industry supported project (Siemens Healthcare, Siemens Research Project). TP, VM, DN, BG, AEP, MW, and TM are employees of Siemens Healthcare. There are no further conflicts of interest. The features mentioned herein are based on research, and are not commercially available. Its future availability cannot be guaranteed due to regulatory reasons.

**Acknowledgments**

This work was partially supported by grants from the German Ministry of Education and Research (BMBF), DZHK (“Deutsches Zentrum für Herz-Kreislauf-Forschung” – German Centre for Cardiovascular Research), the European Union (FP7 BestAgeing) and Siemens Healthcare (Siemens Healthcare/University Heidelberg Joint Research Project: Care4DCM).
Supplementary material

Supplementary material associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j. gpb.2016.04.006.

References

[1] Ghista DN, Sandler H. An analytic elastic-viscoelastic model for the shape and the forces in the left ventricle. J Biomech 1969;2:35–47.

[2] Kayvanpour E, Mansi T, Sedaghat-Hamedani F, Amr A, Neumann D, Georgescu B, et al. Towards personalized cardiology: Multi-scale modeling of the failing heart. PLoS One 2015;10:e0134869.

[3] Tobon-Gomez C, Duchateau N, Sebastian R, Marchesseau S, Camara O, Donal E, et al. Understanding the mechanisms amenable to CRT response from pre-operative multimodal image data to patient-specific computational models. Med Biol Eng Comput 2013;51:1235–50.

[4] Niederer SA, Smith NP. An improved numerical method for strong coupling of excitation and contraction models in the heart. Prog Biophys Mol Biol 2008;96:90–111.

[5] Sermesant M, Chabiniok R, Chinchapatnam P, Mansi T, Billet F, Vasan RS, Levy D. Defining diastolic heart failure: a call for...[22]

[6] Relan J, Chinchapatnam P, Sermesant M, Rhode K, Ginks M, Delingette H, et al. Coupled personalization of cardiac electro-physiology models for prediction of ischaemic ventricular tachycardia. Interface Focus 2011;1:396–407.

[7] Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997;349:1269–76.

[8] Lopes A, Mathers C, Ezzati M, Jamison D, Murray C. Global disability by cause 1990–2020: global burden of disease study. Lancet 1997;349:1498–504.

[9] Santulli G. Epidemiology of cardiovascular disease in the 21st century: updated numbers and updated facts. JCVd 2013;1:1–2.

[10] Murray C, Lopez A. Alternative projections of mortality and disability by cause 1990–2020: global burden of disease study. Lancet 1997;349:1498–504.

[11] Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation 2010;121:e46–e215.

[12] Kayvanpour E, Katus HA, Meder B. Determined to fail—the role of genetic mechanisms in heart failure. Curr Heart Fail Rep 2015;12:333–8.

[13] McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur J Heart Fail 2013;15:361–2.

[14] Sacks CA, Jarcho JA, Cuffman GD. Paradigm shifts in heart-failure therapy—a timeline. N Engl J Med 2014;371:989–91.

[15] Ketchum ES, Levy WC. Establishing prognosis in heart failure: a multimarker approach. Prog Cardiovasc Dis 2011;54:86–96.

[16] Blaus A, Madabushi R, Pacanowski M, Rose M, Schuck RN, Stockbridge N, et al. Personalized cardiovascular medicine today: a Food and Drug Administration/Center for Drug Evaluation and Research perspective. Circulation 2015;132:1425–32.

[17] Trayanova NA, O’Hara T, Bayer JD, Boyle PM, McDowell KS, Constantino J, et al. Computational cardiology: how computer simulations could be used to develop new therapies and advance existing ones. Europace 2012;14:v82–9.

[18] Gomes JA, Mehta D, Ip J, Winters SL, Camunas J, Ergin A, et al. Predictors of long-term survival in patients with malignant ventricular arrhythmias. Am J Cardiol 1997;79:1054–60.

[19] Likoff MJ, Chandler SL, Kay HR. Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 1997;59:634–8.

[20] Cohn JN, Johnson GR, Shabetai R, Loeb H, Tristani F, Rector T, et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87:15–16.

[21] Juilliére Y, Barbier G, Feldmann L, Grenztinger A, Danchin N, Cherrier F. Additional predictive value of both left and right ventricular ejection fractions on long-term survival in idiopathic dilated cardiomyopathy. Eur Heart J 1997;18:276.

[22] Hallstrom A, Pratt C, Greene H, Huther M, Gottlieb S, DeMaria A, et al. Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: analysis of the Cardiac Arrhythmia Suppression Trial. J Am Coll Cardiol 1995;25:1250.

[23] Fortin BA, Shaw LK, McCants Jr CB, Fortin DF, Lee KL, Califf RM, et al. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol 1997;30:1002–8.

[24] Gaasch WH, Zile MR. Left ventricular diastolic dysfunction and diastolic heart failure. Annu Rev Med 2004;55:373–94.

[25] Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation 2002;105:1503–8.

[26] Yancy CW, Jessup M, Bozkurt B, Butler J, Casey Jr DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147–239.

[27] Zile MR, Nappi J. Diastolic heart failure. Curr Treat Options Cardiovasc Med 2002;4:439–50.

[28] Packer M. Abnormalities of diastolic function as a potential cause of exercise intolerance in chronic heart failure. Circulation 1990;81:I178–86.

[29] Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 2000;101:2118–21.

[30] Yturralde RF, Gaasch WH. Diagnostic criteria for diastolic heart failure. Prog Cardiovasc Dis 2005;47:314–9.

[31] Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 2002;105:1387–93.

[32] Noble D. Modeling the heart—from genes to cells to the whole organ. Science 2002;295:1678–82.

[33] Burch GE, Ray CT, Cronvich JA. The George Fahr Lecture: certain mechanical peculiarities of the human cardiac pump in normal and diseased states. Circulation 1952;5:504–13.

[34] Koushanpour E, Collings WD. Validation and dynamic applications of an ellipsoid model of the left ventricle. J Appl Physiol 1966;21:1655–61.

[35] Vetter FJ, McCulloch AD. Three-dimensional analysis of regional cardiac function: a model of rabbit ventricular anatomy. Prog Biophys Mol Biol 1998;69:157–83.

[36] Horan LG, Hand RC, Johnson JC, Sridharan MR, Rankin TB, Flowers NC. A theoretical examination of ventricular repolarization and the secondary T wave. Circ Res 1978;42:750–7.

[37] Aoki M, Okamoto Y, Musha T, Harumi K. Three-dimensional simulation of the ventricular depolarization and repolarization processes and body surface potentials: normal heart and bundle branch block. IEEE Trans Biomed Eng 1987;34:454–62.

[38] Zienkiewicz O, Kelly D, Bettess P. The coupling of the finite element method and boundary solution procedures. Int J Numer Meth Eng 1977;11:355–75.
Dokos S, Smaill BH, Young AA, LeGrice IJ. Shear properties of
Helm P, Beg MF, Miller MI, Winslow RL. Measuring and
Clayton RH, Bernus O, Cherry EM, Dierckx H, Fenton FH,
Vetter FJ, McCulloch AD. Three-dimensional stress and strain in
Frangi AF, Niessen WJ, Viergever MA. Three-dimensional
Weiss JL, Frederiksen JW, Weisfeldt ML. Hemodynamic deter-
Holzapfel GA, Ogden RW. Constitutive modelling of passive
Vinson CA, Gibson DG, Yettram AL. Analysis of left ventricular
Bayer JD, Blake RC, Plank G, Trayanova NA. A novel rule-
Bishop MJ, Plank G, Burton RA, Schneider JE, Gavaghan DJ,
Berry C, Doughty R, Granger C, Kober L, Massie B, McAlister,
Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK,
Wang HM, Gao H, Luo XY, Berry C, Griffith BE, Ogden RW,
Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H,
Paulus WJ, Tschope C, Kasner M, Westermann M, Gaub R, Poller WC,
Schultheiss HP. The role of NT-proBNP in the diagnostics of
isolated diastolic dysfunction: correlation with echocardiographic
and invasive measurements. Eur Heart J 2005;26:2277–84.
Hartmann F, Packard M, Coats AJ, Fowler MB, Krum H, Mohacsi P, et al. NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy. Eur J Heart Fail 2004;6:343–50.
Kasner M, Westermann D, Steendijk P, Gaub R, Wilkenshoff U, Weitmann K, et al. Utility of Doppler echocardiography and tissue Doppler imaging in the estimation of diastolic function in heart failure with normal ejection fraction: a comparative Doppler-conductance catheterization study. Circulation 2007;116: 637–47.
Berry C, Doughty R, Granger C, Kofer L, Massie B, McAlister F, et al. The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 2012;33:1750–7.